Literature DB >> 23258931

The impact of cardiovascular disease and risk factor treatment on ethnic disparities in kidney transplant.

David J Taber1, Nicole A Pilch, Holly B Meadows, John W McGillicuddy, Charles F Bratton, Kenneth D Chavin, Prabhakar K Baliga, Leonard E Egede.   

Abstract

There is limited data on the use of cardiovascular disease (CVD) risk factor medications following renal transplant, especially when comparing use across ethnicities. The aim of this study was to compare the incidence, treatment, and impact of CVD between ethnicities in kidney transplant recipients. This was a retrospective cohort study of adults who underwent transplant between 2000 and 2008 within our academic medical transplant center. Pediatrics, multiorgan transplants, and those lost to follow-up were excluded. Data collection included all transplant and sociodemographic characteristics, medication use, CVD risk factor management, and follow-up events, including acute rejection, graft loss, and death. A total of 987 patients were included and followed for a mean of 6.7 ± 3.0 years. The baseline demographics revealed black patients were equally likely to have preexisting CVD (24% vs 25%, P = .651), but more likely to have preexisting diabetes (35% vs 23%, P < .001) or hypertension (97% vs 94%, P = .029). Black patients had poorer treatment of CVD risk factors, with lower rates of control of diabetes (35% vs 51%, P < .05) and dyslipidemia (37% vs 42%, P < .05). Black renal transplant recipients who had preexisting CVD had reduced graft survival rates compared to white patients (10-year rate 50% vs 60%, P = .033), but similar rates of graft survival were found in those without CVD (10-year rate 70% vs 71% in white patients, P = .483). CVD is common in transplant recipients, with black patients having higher rates and poorer control of diabetes and dyslipidemia.

Entities:  

Mesh:

Year:  2012        PMID: 23258931     DOI: 10.1177/1074248412469298

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol Ther        ISSN: 1074-2484            Impact factor:   2.457


  8 in total

1.  Overall Graft Loss Versus Death-Censored Graft Loss: Unmasking the Magnitude of Racial Disparities in Outcomes Among US Kidney Transplant Recipients.

Authors:  David J Taber; Mulugeta Gebregziabher; Elizabeth H Payne; Titte Srinivas; Prabhakar K Baliga; Leonard E Egede
Journal:  Transplantation       Date:  2017-02       Impact factor: 4.939

2.  Impact of Cardiovascular Risk Factors on Graft Outcome Disparities in Black Kidney Transplant Recipients.

Authors:  David J Taber; Kelly J Hunt; Cory E Fominaya; Elizabeth H Payne; Mulugeta Gebregziabher; Titte R Srinivas; Prabhakar K Baliga; Leonard E Egede
Journal:  Hypertension       Date:  2016-07-11       Impact factor: 10.190

3.  Outcome disparities between African Americans and Caucasians in contemporary kidney transplant recipients.

Authors:  David J Taber; Leonard E Egede; Prabhakar K Baliga
Journal:  Am J Surg       Date:  2016-11-18       Impact factor: 2.565

4.  The impact of time-varying clinical surrogates on disparities in African-American kidney transplant recipients - a retrospective longitudinal cohort study.

Authors:  David J Taber; Zemin Su; James N Fleming; Nicole A Pilch; Thomas Morinelli; Patrick Mauldin; Derek Dubay
Journal:  Transpl Int       Date:  2018-09-16       Impact factor: 3.782

5.  Significant racial differences in the key factors associated with early graft loss in kidney transplant recipients.

Authors:  David J Taber; Kevin Douglass; Titte Srinivas; John W McGillicuddy; Charles F Bratton; Kenneth D Chavin; Prabhakar K Baliga; Leonard E Egede
Journal:  Am J Nephrol       Date:  2014-06-25       Impact factor: 3.754

6.  Pharmacist-Led, Technology-Assisted Study to Improve Medication Safety, Cardiovascular Risk Factor Control, and Racial Disparities in Kidney Transplant Recipients.

Authors:  David J Taber; Mulugeta Gebregziabher; Aurora Posadas; Caitlin Schaffner; Leonard E Egede; Prabhakar K Baliga
Journal:  J Am Coll Clin Pharm       Date:  2018-06-21

7.  Racial Differences in Medication Utilization for Secondary Prevention of Cardiovascular Disease in Kidney Transplant Recipients: A Post Hoc Analysis of the FAVORIT Trial Cohort.

Authors:  Mohammad Kazem Fallahzadeh; Elaine Ku; Chi D Chu; Charles E McCulloch; Delphine S Tuot
Journal:  Kidney Med       Date:  2022-02-23

8.  Does African American Race Impact Statin Efficacy in Renal Transplant Outcomes?

Authors:  Mukoso N Ozieh; David J Taber; Leonard E Egede
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.